Atlas Trials

Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

Clinical trial NCT04541043 · COMPLETED

Trial details

NCT number
NCT04541043
Sponsor
Calliditas Therapeutics AB
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Primary IgA Nephropathy
Start date
2020-11-17
Primary completion
2024-02-26
Enrollment
119

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.